manilatimes: Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare ... Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare ... Acute Onset of Disseminated Superficial Actinic Porokeratosis and Solid Malignancy Porokeratosis (PK) is a hereditary or acquired disorder of epidermal keratinization.

Understanding the Context

PK presents with one or more ... Mena FN: Palvella Therapeutics Announces New QTORINTM Product Candidate, QTORINTM Pitavastatin, For The Treatment Of Disseminated Superficial Actinic Porokeratosis (DSAP), A Rare ... Palvella Therapeutics Announces New QTORINTM Product Candidate, QTORINTM Pitavastatin, For The Treatment Of Disseminated Superficial Actinic Porokeratosis (DSAP), A Rare ... Palvella's second product candidate, QTORIN pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis.

Key Insights

For more information, please visit ... Finanznachrichten: Palvella Therapeutics Inc.: Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic ... Palvella Therapeutics Inc.: Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic ...